BioInvent's BI-1808, when paired with Merck's Keytruda, shows a threefold increase in overall response for advanced ovarian cancer, a historically difficult-to-treat malignancy.
Back
Back
BioInvent drug triples ovarian cancer response in Phase 2a trial
BioInvent International AB plans to present new data showing its experimental drug BI-1808, when combined with Merck’s Keytruda, tripled the overall response rate in patients with advanced ovarian cancer. The results from the Phase 2a trial represent a significant step forward for a cancer with limited effective treatment options in later stages.
The announcement, detailing findings to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, confirms the combination therapy's potential to enhance anti-tumor immune responses. "BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined with PD-1 blockade," the company stated in its press release.
The Phase 2a study evaluated the safety and efficacy of BI-1808, a novel immune-modulatory antibody, alongside the anti-PD-1 therapy Keytruda (pembrolizumab) in patients with advanced ovarian cancer who have few remaining treatment avenues. While full details will be shared at the conference from May 29 to June 2, the headline result points to a strong synergistic effect between the two drugs.
For investors, this clinical data provides a crucial validation of BioInvent's scientific platform and its lead candidate, BI-1808. A tripling of response rates in a difficult-to-treat cancer like advanced ovarian could significantly de-risk the asset, likely boosting BioInvent's (Nasdaq Stockholm: BINV) valuation and attracting further partnership interest beyond the existing collaboration with Merck.
A New Mechanism for a Tough Cancer
BI-1808 is an antibody designed to modulate the immune system to better recognize and attack cancer cells. It targets a specific receptor to activate anti-cancer immune cells. This mechanism is distinct from, and potentially complementary to, PD-1 inhibitors like Keytruda, which work by releasing a natural brake on the immune system. The trial results suggest that combining these two approaches—actively stimulating the immune response with BI-1808 while simultaneously releasing the brakes with Keytruda—creates a more powerful anti-tumor effect than Keytruda can achieve on its own.
Ovarian cancer remains a significant challenge in oncology, with high rates of recurrence and mortality, particularly for patients diagnosed at an advanced stage. The positive data from this trial positions BI-1808 as a promising new agent in a field with high unmet need, potentially offering a new option for thousands of patients.
Competitive and Financial Impact
The strong Phase 2a results are likely to generate significant interest at the upcoming ASCO meeting, a major venue for oncology drug development news. This positive clinical signal is expected to cause a significant increase in BioInvent's stock price and could accelerate the drug's development pathway toward a pivotal Phase 3 trial.
Furthermore, the data validates the potential of BioInvent's broader pipeline of immune-modulatory antibodies. Success in this combination setting could also lead to an expanded collaboration with Merck or attract buyout interest from larger pharmaceutical companies looking to bolster their oncology portfolios. While BioInvent's cash runway was not disclosed, successful data readouts are critical for smaller biotech firms to secure the funding necessary to advance their programs.
This article is for informational purposes only and does not constitute investment advice.
